Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended access of momelotinib for subjects with myelofibrosis
2023-508018-41-00Phase 2Authorised
- Sponsor
- GSK
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 18
01
Overview
Phase 2, open-label, single-arm trial of mivavotinib in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) and myelofibrosis (MF), sponsored by GSK. Primary endpoint: Safety: incidence, severity, seriousness, and causal relationship of adverse events. Planned start Jul 2024; status: authorised.
02
Drugs
mivavotinib
03
Conditions
primary myelofibrosis (PMF)post-polycythemia vera myelofibrosis (PPV-MF)myelofibrosis (MF)
Beyond the preview
Go deeper on 2023-508018-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508018-41-00.